CARDIOLOGY  |  DIABETES & HEART HEALTH

Type 2 Diabetes and Your Heart: What the New NICE Guidelines Mean for You

Updated NICE guidelines published in 2026 represent the most significant change to diabetes care in the UK for a generation. For the first time, protecting the heart and kidneys — not just controlling blood sugar — is placed at the centre of treatment. Here, Dr Malgorzata Wamil, Consultant Cardiologist and contributor to NICE preventive cardiology guidelines, explains what this means for patients and the clinicians who care for them.

Written by Dr Gosia Wamil  |  Consultant Cardiologist

Why diabetes is, above all, a heart disease

If you have been diagnosed with type 2 diabetes, the most important thing to understand is this: the greatest threat to your long-term health is not your blood sugar — it is your heart.

People with type 2 diabetes are, on average, four times more likely to develop cardiovascular disease (CVD) than people without diabetes. Cardiovascular disease — including heart attacks, strokes, and heart failure — is the leading cause of death in people living with this condition. It accounts for around 50% of all deaths in the type 2 diabetes population.

The reason for this link is biological. Persistently elevated blood glucose damages the walls of blood vessels over time — a process called endothelial dysfunction. This makes arteries stiffer, promotes the build-up of fatty plaques (atherosclerosis), and accelerates the narrowing of coronary arteries that supply the heart muscle. Diabetes also disrupts the body's ability to regulate blood pressure and cholesterol, and promotes a chronic state of low-grade inflammation — all of which further increase cardiovascular risk.

Beyond the heart, diabetes places significant strain on the kidneys (diabetic nephropathy) and can cause structural changes to the heart muscle itself — a condition known as diabetic cardiomyopathy — which can lead to heart failure even in the absence of blocked coronary arteries.

For these reasons, managing type 2 diabetes effectively means managing the cardiovascular system. Blood glucose control matters — but it is one part of a much larger picture.

“The greatest threat to someone with type 2 diabetes is not their blood sugar — it is their heart. Treatment must reflect that reality.”

The shift from glucose-centric to cardiovascular-first care

For many years, diabetes management in the UK — and globally — focused primarily on reducing HbA1c, the measure of average blood glucose over the preceding three months. Treatments were selected largely based on how effectively they reduced this single number.

The evidence began to shift significantly over the past decade. Large randomised controlled trials — involving tens of thousands of patients across multiple countries — demonstrated that certain newer diabetes medicines reduced the risk of heart attacks, strokes, hospitalisation for heart failure, and kidney deterioration, independent of their glucose-lowering effect. In some trials, people taking these medicines had fewer cardiovascular events, regardless of what happened to their HbA1c.

This body of evidence has driven a fundamental change in how diabetes is now understood: not simply as a condition of high blood sugar, but as a cardiometabolic disease requiring integrated management of glucose, blood pressure, cholesterol, weight, kidney function, and overall cardiovascular risk.

The 2026 update to the NICE guideline NG28 formally reflects this shift. For the first time, UK national guidance explicitly recommends that treatment choices should be guided primarily by a patient’s cardiovascular and kidney risk profile, with glucose-lowering as an important, but secondary, consideration.

As a cardiologist with a long-standing interest in diabetes management, and as a contributor to NICE preventive cardiology guidelines since 2019, I have been part of the clinical community advocating for this shift. Seeing it now embedded in national guidance is a significant and long-overdue step forward.

What the new guidelines recommend — and why

The key practical changes introduced by the 2026 NICE update are as follows.

Earlier use of SGLT-2 inhibitors

SGLT-2 inhibitors (including dapagliflozin and empagliflozin) work by causing the kidneys to excrete excess glucose in the urine. Beyond this glucose-lowering effect, they have been shown in multiple large trials to significantly reduce the risk of hospitalisation for heart failure, slow the progression of chronic kidney disease, and lower the risk of cardiovascular death.

Under the new guidance, most people with type 2 diabetes should now be offered an SGLT-2 inhibitor early in their treatment — in most cases alongside metformin from the point of diagnosis — rather than waiting until blood glucose targets are not being met. For patients with established heart failure or chronic kidney disease, an SGLT-2 inhibitor is now the recommended first-line agent.

Wider access to GLP-1 receptor agonists

GLP-1 receptor agonists (including semaglutide, dulaglutide, and liraglutide) mimic a natural gut hormone that stimulates insulin release, reduces appetite, and slows gastric emptying. In cardiovascular outcome trials, they have been shown to reduce the risk of major cardiovascular events — including heart attack and stroke — particularly in people who already have cardiovascular disease.

The updated guidelines significantly expand access to these medicines. They are now recommended for people with established atherosclerotic cardiovascular disease (such as coronary artery disease or prior stroke), those diagnosed with diabetes under the age of 40, and those living with obesity. An estimated 810,000 additional people in the UK may now be eligible.

Tirzepatide — a newer dual-action agent targeting both GLP-1 and GIP receptors — is also now included within the guidance, reflecting the rapidly evolving evidence base for this class of medicines.

Personalised, risk-stratified treatment pathways

Rather than a single treatment algorithm applied to all patients, the new guidelines set out distinct management pathways based on a patient’s individual risk profile. Separate recommendations now exist for patients with:

Established cardiovascular disease (prior heart attack, stroke, or coronary revascularisation)

Heart failure (with both reduced and preserved ejection fraction)

Chronic kidney disease

High cardiovascular risk without established disease

Younger-onset diabetes (diagnosed under 40)

Obesity as a significant comorbidity

This stratified approach reflects what cardiologists and specialist diabetes physicians have long known in clinical practice: the right treatment depends on the whole patient, not just one number.

The role of lifestyle: still essential, now better supported

Medicines alone cannot fully address cardiovascular risk in diabetes. The guidelines reaffirm that lifestyle modification remains one of the most effective interventions available — and in some patients, the most powerful.

The evidence is clear: sustained weight loss of 10–15% of body weight can lead to remission of type 2 diabetes in a significant proportion of patients. Regular aerobic exercise improves insulin sensitivity, reduces blood pressure, lowers cardiovascular mortality, and directly improves heart function. Smoking cessation reduces cardiovascular risk substantially within just one to two years. Dietary changes — reducing refined carbohydrates and saturated fats, increasing fibre — improve both glucose control and lipid profiles.

The challenge, as any clinician will recognise, is that lifestyle change is difficult to achieve and maintain without structured, personalised support. The new guidelines place greater emphasis on offering structured education programmes and dietary support, and on integrating weight management into diabetes care from the outset rather than as an afterthought.

In practice, the most effective approach combines targeted pharmacotherapy with active lifestyle support — addressing weight, blood pressure, cholesterol, and glucose together, rather than sequentially.

What this means for patients: questions to ask your doctor

If you have type 2 diabetes, the 2026 guideline update may have practical implications for your current treatment. It is worth discussing the following with your GP or diabetes team:

Have my cardiovascular and kidney risk been formally assessed? This should now be a central part of every diabetes review.

Should I be taking an SGLT-2 inhibitor? Based on the new guidance, many patients who are not currently on one may be eligible.

Am I eligible for a GLP-1 receptor agonist? Particularly relevant if you have heart disease, were diagnosed under 40, or are living with obesity.

Is my blood pressure and cholesterol well controlled? These are as important as HbA1c in reducing your overall risk.

Is there support available for weight management and lifestyle change? Structured programmes are more effective than general advice alone.

What this means for GPs and referring clinicians

The 2026 update will require a meaningful adjustment to prescribing practice in primary care. The key implications for GPs and practice-based diabetes teams are:

Cardiovascular risk assessment should be performed at diagnosis and reviewed regularly — not only when HbA1c targets are breached.

SGLT-2 inhibitors should be considered at initiation of treatment for most patients, and are first-line in those with heart failure or CKD.

GLP-1 receptor agonist eligibility should be reviewed in light of expanded indications — including cardiovascular disease, younger-onset diabetes, and obesity.

Patients with complex cardiometabolic profiles — combining diabetes, hypertension, obesity, and cardiovascular disease — may benefit from specialist input, particularly where treatment optimisation is uncertain or multiple risk factors require coordinated management.

Our Cardio-Metabolic Clinic accepts referrals from GPs and specialist colleagues for patients in whom a dedicated cardiovascular risk assessment and personalised management plan would be beneficial. We work alongside existing diabetes and primary care teams to provide specialist input on treatment optimisation, novel cardiometabolic therapies, and structured lifestyle support.

A more complete approach to a complex condition

Type 2 diabetes is not a single problem with a single solution. It is a condition that affects the heart, blood vessels, kidneys, and metabolic system simultaneously. Managing it well requires attention to all of these — not just blood sugar.

The 2026 NICE guidelines bring UK clinical practice in line with the best available evidence and with what specialist centres have been doing for some years. For patients, it means a treatment approach that is more likely to protect the heart, preserve kidney function, and extend healthy life. For clinicians, it provides a clear framework for delivering that care.

If you have type 2 diabetes and have not recently had a comprehensive cardiovascular risk review, now is an excellent time to have that conversation with your doctor.

— 

References: NICE NG28 (2026 update); EMPA-REG OUTCOME trial; DAPA-HF trial; LEADER trial; DECLARE-TIMI 58 trial; UK Prospective Diabetes Study (UKPDS); Haffner et al., NEJM 1998 (CVD risk in T2DM); NICE impact report on type 2 diabetes, 2026.